WHO endorses Burnet HIV diagnostic
A Burnet-designed rapid point-of-care test for HIV has been accepted for the World Health Organization’s (WHO) list of prequalified in vitro diagnostics.
The VISITECT® CD4 Advanced Disease Test, developed by Burnet’s Global Health Diagnostics Group and commercialised and manufactured by Omega Diagnostics, was listed after WHO auditors found it effective at measuring a patient’s CD4 T cell count to assess whether urgent interventions are required in a patient diagnosed with advanced HIV.
Burnet Deputy Director, Associate Professor David Anderson said WHO prequalification, the highest level of regulatory approval for a product of its type, meant aid agencies delivering HIV services in low-to-middle income countries could use the test to put more people onto the appropriate HIV treatment sooner.
The low-cost and portable test, which functions in a similar manner to a pregnancy test, provides a visual reading of whether a patient’s CD4 T+ cell count in their blood is below 200/μL, meaning their immune system has been compromised.
“In many countries around half of the patients who are diagnosed each year with HIV for the first time will actually need a range of other interventions, which they would miss out on if they didn’t have the CD4 test,” Associate Professor Anderson said.
Associate Professor Anderson said simplicity and robustness were key principles in designing the CD4 point-of-care test, and it was encouraging to see the WHO’s endorsement of these principles.
The technology and philosophy behind the CD4 test, he said, was being applied to other Burnet point-of-care tests currently in development for other diseases, including syphilis, COVID-19 and sepsis.
“We’re applying those principles in the same manner: making them work in the simplest possible way in any setting,” Associate Professor Anderson said.
He said working with good partners, including Omega Diagnostics, which has commercialised and manufactured the VISITECT® CD4 Advanced Disease Test, as well as strong collaborations with Rush University and Duke University in the USA, showed Burnet’s diagnostics team could make a lasting impact on global health.
Omega Diagnostics has attracted significant orders and interest from African, Latin American and Asian countries for the test.
“I am very excited about it. It will make a huge difference to the ability to get the most value out of the interventions available for HIV,” Associate Professor Anderson said.
More about Burnet’s COVID-19 diagnostic in the video below.
Associate Professor David Anderson discusses the development of a point-of-care test for novel coronavirus COVID-19.
Associate Professor David Anderson: Here at the Burnet laboratories we're developing a point-of-care test for COVID-19, similar to this one we developed years ago for HIV/AIDS to identify people who have been infected with COVID-19, the virus SARS-COV-2.
We need to identify people who have been infected firstly to see who may still be infectious and needs to be isolated or treated and to find their contacts, but also to identify those who have recovered from the infection and may be safe to return to work, especially in high-risk occupations. But accuracy is really the key here we need to get it right.
We're uniquely placed at Burnet to achieve this because of novel technology developed, and the partnerships we developed over the years, and these skills and experience that we bring to this from addressing the HIV epidemic, the hep C epidemic etc over the past 3 decades.
We're doing our part to address the COVID-19 emergency and we hope that you can help us to do your part. End of transcript.
Learn more about commercialisation and research translation at Burnet.
